Epic calls on Particle Health to approve release of resolution in patient privacy dispute

VERONA, Wis., Sept. 27, 2024 /PRNewswire/ — Epic and our customers protect the privacy of many Americans’ health data. At the direction of our customer governing council, we filed a dispute through the Carequality interoperability network against Particle Health because some Particle customers used the network to take people’s medical records under false pretenses. For example, a business, Integritort, claimed to be treating patients when in fact it was gathering medical records for personal injury law firms to review for potential class action lawsuits.

Carequality’s Steering Committee has overseen the dispute and issued their resolution. Particle has publicly mischaracterized the resolution. Particle should join Epic in asking Carequality to release the resolution immediately so that patients, healthcare organizations, other network participants, interoperability advocates, lawmakers, and journalists can evaluate the facts for themselves.

Epic and our customer community will continue to lead on interoperability and defend patient privacy.

Epic is a global healthcare software company that helps people get well, helps people stay well, and helps future generations be healthier. Founded in a basement in 1979 with three half-time employees, Epic is now the leading EHR software developer in the United States. Epic supports healthcare organizations in 16 countries, with more than 3,000 hospitals using Epic and over 190 million patients using Epic’s MyChart patient portal to manage their care online.

For more information contact: media@epic.com. Visit www.epic.com/about.

View original content to download multimedia:https://www.prnewswire.com/news-releases/epic-calls-on-particle-health-to-approve-release-of-resolution-in-patient-privacy-dispute-302260935.html

SOURCE Epic

Staff

Recent Posts

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

6 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

9 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

9 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

9 hours ago